Yazar "Atilla, Aynur" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Non-HACEK Gram-negative bacillus endocarditis
    (Elsevier Masson SAS, 2019) Mercan, Mustafa Ertuğrul; Arslan, Ferhat; Özyavuz Alp, Şehnaz; Atilla, Aynur; Seyman, Derya; Guliyeva, Günay; Kayaaslan, Bircan Ünal; Sarı, Sema; Mutay Suntur, Bedia; Işık, Burcu; Mert, Ali
    Patients and methods: Retrospective analysis of clinical data using 26 diagnosed non-HACEK Gram-negative infective endocarditis cases from nine hospitals in Turkey. Results: Mean age of patients was 53 (28–84) years, with a 23% case fatality. Nineteen (73%) of the 26 patients had at least one predisposing factor. The presence of a central venous catheter was the most common predisposing factor (7/26 patients). Pseudomonas aeruginosa (7/26 patients) and Escherichia coli (7/26 patients) were the most common pathogens. The median duration of the antibiotic therapy was 42 days (range 3–84 days). Surgical procedures were performed in 10 patients. The case fatality was similar in patients who did or did not undergo surgery (20% vs. 25%).
  • Küçük Resim
    Öğe
    Risk factors for recurrences in patients with hepatitis C virus after achieving a sustained virological response: A multicentre study from Turkey
    (EDIMES Edizioni Medico Scientifiche, 2018) Arslan, Ferhat; Ceylan, Bahadır; Şahin, Ahmet Rıza; Günal, Özgür; Kayaaslan, Bircan Ünal; U?urlu, Kenan; Tano?lu, Alpaslan; İskender, Gülşen; Tosun, Selma Yegane; Atilla, Aynur; Sargın, Fatma; Batırel, Ayşe; Karagöz, Ergenekon; Sonsuz, Abdullah; Mert, Ali
    In this study, we aimed to determine the late relapse rate in hepatitis C patients with sustained virological response after interferon-based regimens, and evaluated the predictors of late relapse while comparing the real-life data of our country with that of others. A multicenter retrospective study was performed to investigate the data of patients infected with HCV who obtained sustained virological response after classical or pegylated interferon alpha (PegIFN?) and ribavirin (RBV) for 48 weeks. Sustained virological response was based on negative HCV RNA level by PCR at the end of six months after the therapy. The information of patients enrolled in the study was retrieved from the hospital computer operating system and outpatient follow-up archives. We evaluated the age, gender, HCV RNA levels, HCV genotype, six-month and further follow-up of patients with sustained virologic response, presence of cirrhosis, steatosis and relapse. In all, 606 out of 629 chronic hepatitis C patients (mean age was 53±12 years; 57.6 % of them were female) with sustained virological response were evaluated. We excluded 23 patients who relapsed within six months after the end of treatment (EOT). The mean follow-up period of the patients was 71 months (range: 6-136) after therapy. Late relapse rate was 1.8% (n=11) in all patients. Univariate Cox proportional hazard regression models identified that cirrhosis and steatosis were associated with the late relapse [(p=0.027; Hazard Ratio (HR) 2.328; 95% confidence interval (CI): 1.309-80.418), (p=0.021; HR 1.446; 95% CI: 1.243-14.510, respectively]. In multivariable Cox regression analysis, steatosis was the only independent risk factor for late relapse (p=0.03; HR 3.953; 95% CI: 1.146-13.635). Although the late relapse rate was approximately 2% in our study, clinicians should consider that pretreatment steatosis may be an important risk factor for late relapse.